Exosomes derived from tunicamycin (TM)-treated cancer cells contain abundant miR-23a-3p, which inhibit PTEN expression and subsequently elevated phosphorylated AKT and PD-L1 expression in macrophages, thus helping cancer cells to escape from antitumor immunity (77). Here, PTEN is linked to cancer.